

# LEOPARD Training and Validation Data Collection Study

NCT06675604

---

<b>Status</b>	RECRUITING
<b>Sponsor</b>	Assistance Publique - Hôpitaux de Paris
<b>Enrollment</b>	4,500 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Adult \[age 18;70\] patients listed for:
- decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset 1) OR
- other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc...) (subset 2) OR
- HCC\* as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.)
- Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points and MELD exceptions are affected or not.

... and 2 more (see full listing online)

### Exclusion (5)

- Tumor vascular invasion (portal or hepatic veins) evidenced by imaging at pre transplantation work-up, including portal vein thrombosis stage 1
- Extra-hepatic metastasis of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or histologically proven
- Patients who are under safeguard of justice or tutorship or curatorship
- Patient on AME (state medical aid)
- Participation to LEOPARD PVC 1 study of WP2

## Locations (22 total)

---

Universitätsklinik für Allgemeinchirurgie, Klinische Abteilung für Transplantation, Vienna, Austria  
Department of Gastroenterology and Hepatology Universitair Ziekenhuis Gent, Ghent, Belgium  
CHU Jean Minjoz Besançon, Department of Hepatology, Besançon, France  
... and 19 more locations